Form 144 is a notice of proposed sale of restricted securities by an affiliate under Rule 144, allowing public resale without registration. Rocket Lab director Merline A. Saintil plans to sell 5,000 common shares through Morgan Stanley on or around 12/17/2025, with an aggregate market value of $277,450 based on current pricing (implying ~$55.49/share). Shares were acquired on 8/22/2023 via restricted stock units from the issuer. In the past three months, Saintil sold 10,000 shares on 12/4/2025 for $480,000 (~$48/share) and 15,000 on 12/12/2025 for $975,000 (~$65/share), totaling 25,000 shares for ~$1.455M. The filing confirms reliance on a Rule 10b5-1 trading plan adopted 9/17/2025, which provides a defense against insider trading claims, and Saintil represents no undisclosed material adverse information. Against 534M shares outstanding, this represents negligible dilution (<0.001%). For Rocket Lab, a space launch provider, such insider sales of vested compensation are routine and tied to liquidity needs rather than company outlook.

This routine, pre-planned sale by a director of a tiny fraction of shares (<0.001%) has minimal near-term impact on RKLB stock or valuation, likely reflecting personal liquidity from vested RSUs amid volatile share prices. Strategically neutral, as 10b5-1 compliance signals no insider concerns. Investors should monitor aggregate insider selling volume and Form 4 filings for patterns, but isolated RSU monetization is common in high-growth tech/space firms like Rocket Lab.